Shang Panfeng
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients (NCT06778538) | Shang Panfeng | 2024-07-01 |
Track Shang Panfeng automatically
Every clearance here is in the API, with alerts when new ones post.